171 related articles for article (PubMed ID: 20221692)
1. Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.
Fernández-Cuesta L; Anaganti S; Hainaut P; Olivier M
Breast Cancer Res Treat; 2011 Jan; 125(1):35-42. PubMed ID: 20221692
[TBL] [Abstract][Full Text] [Related]
2. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
[TBL] [Abstract][Full Text] [Related]
3. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
Liu W; Ip MM; Podgorsak MB; Das GM
Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
[TBL] [Abstract][Full Text] [Related]
4. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
Anaganti S; Fernández-Cuesta L; Langerød A; Hainaut P; Olivier M
Cancer Lett; 2011 Jan; 300(2):215-24. PubMed ID: 21071137
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Lu W; Katzenellenbogen BS
Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
8. p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.
Berger CE; Qian Y; Liu G; Chen H; Chen X
J Biol Chem; 2012 Aug; 287(36):30117-27. PubMed ID: 22787161
[TBL] [Abstract][Full Text] [Related]
9. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.
Herynk MH; Hopp T; Cui Y; Niu A; Corona-Rodriguez A; Fuqua SA
Breast Cancer Res Treat; 2010 Jul; 122(2):381-93. PubMed ID: 19842032
[TBL] [Abstract][Full Text] [Related]
10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.
Sayeed A; Konduri SD; Liu W; Bansal S; Li F; Das GM
Cancer Res; 2007 Aug; 67(16):7746-55. PubMed ID: 17699779
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.
Liao XH; Lu DL; Wang N; Liu LY; Wang Y; Li YQ; Yan TB; Sun XG; Hu P; Zhang TC
FEBS J; 2014 Feb; 281(3):927-42. PubMed ID: 24283290
[TBL] [Abstract][Full Text] [Related]
13. Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation.
Gu G; Barone I; Gelsomino L; Giordano C; Bonofiglio D; Statti G; Menichini F; Catalano S; Andò S
J Cell Physiol; 2012 Oct; 227(10):3363-72. PubMed ID: 22213398
[TBL] [Abstract][Full Text] [Related]
14. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer.
Lin Z; Yin P; Reierstad S; O'Halloran M; Coon VJ; Pearson EK; Mutlu GM; Bulun SE
Oncogene; 2010 Feb; 29(8):1114-22. PubMed ID: 19935720
[TBL] [Abstract][Full Text] [Related]
16. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the
Chitrala KN; Nagarkatti M; Nagarkatti P; Yeguvapalli S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31216622
[TBL] [Abstract][Full Text] [Related]
18. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
20. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.
Akaogi K; Nakajima Y; Ito I; Kawasaki S; Oie SH; Murayama A; Kimura K; Yanagisawa J
Oncogene; 2009 Aug; 28(32):2894-902. PubMed ID: 19503094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
